

## Data Sharing Statement

Salloway. Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease. *JAMA Neurol*. Published November 18, 2024.

doi:10.1001/jamaneurol.2024.3937

### Data

**Additional Information:** Clinicaltrials.gov; <https://clinicaltrials.gov/study/NCT03444870>; NCT03444870 Clinicaltrials.gov; <https://clinicaltrials.gov/study/NCT03443973>; NCT03443973 Clinicaltrials.gov; <https://clinicaltrials.gov/study/NCT04374253>; NCT04374253

**Data available:** Yes

**Data types:** Deidentified participant data

**How to access data:** <https://vivli.org/ourmember/roche/>

**When available:** With publication

### Supporting Documents

**Document types:** None

### Additional Information

**Who can access the data:** For eligible studies qualified researchers may request access to individual patient-level clinical data through a data request platform.

**Types of analyses:** For eligible studies qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing this request platform is Vivli. <https://vivli.org/ourmember/roche/>. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: [https://go.roche.com/data\\_sharing](https://go.roche.com/data_sharing). Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient re-identification.

**Mechanisms of data availability:** Available studies are listed and searchable on the Vivli Platform. Data requestors should use the Vivli Data request form to request company's data package(s). If approved, requesters will need to sign a Data Use Agreement and the anonymized data will be shared in the Vivli secure research environment.